Centre National De La Recherche Scientifique

Universitè De Montpellier

Institut Curie

Abivax

Universite Montpellier 2

Societe Splicos

Abivax Sa

Romain Najman

Jamal Tazi

Didier Scherrer

Florence Mahuteau

Aude Garcel

Pierre Roux

Julien Santo

Noelie Campos

Gilles Gadea

Carsten Brock

Nathalie Cahuzac

Cécile Apolit

Florence Mahuteau-Betzer

Florence Mahuteau-betzer

Noëlie Campos

Pauline Fornarelli

Audrey Vautrin

Karim Chebli

Michael Hahne

Julian Venables

Noëlle Campos

Frederic Labeguere

Brice Sautier

Natacha Bienvenu

Elisa Azzali

A compound of formula (I) or any of its pharmaceutically acceptable salt for use in the treatment and/or prevention of a RNA virus infection, and a RNA virus infection from group IV or V of the Baltimore classification wherein Rrepresents a chlorine atom or a hydrogen atom, R represents a (C-C)alkyl group, a (C-C)cycloalkyl group, a halogen atom, a (C-C)alkoxy group, a —SO—NRRgroup, a —SOH group, a —OH group, a —O—SO—ORgroup or a —O—P(═O)—(OR)(OR) group, Rrepresents (i) a CFgroup, (ii) a (C-C)alkyl group, (iii) a (C-C)cycloalkyl or a (C-C)heterocycloalkyl group or (iv) a phenyl group or a naphthyl group, and Rrepresents a hydrogen atom, a (C-C)alkyl group, a (C-C)cycloalkyl or a (C-C)heterocycloalkyl group and further relates to new compounds, to pharmaceutical compositions containing them and to synthesis process for manufacturing them.

Phenyl-n-quinoline derivatives for treating a RNA virus infection

A compound of formula (Ie): wherein Yrepresents an aryl group, Xrepresents a —O— group, a —NH— group, a —S— group, a —CO—NH— group, a —NH—CO—NH— group, a —NH—CO— group, a —CH(OH)— group, a —CH(COOH)NH— group, a —CH(COOCH)NH— group, a —C(OH)(CHOH)—, a group, a divalent 5-membered heteroaromatic ring comprising 1, 2, 3 or heteroatoms, a —SO— group, or a —SO—NH— group, Yrepresents a hydrogen atom, a hydroxyl group, a (C-C)alkoxy group, a —CHC(OH), a COOR, wherein Rrepresents a hydrogen atom or a (C-C)alkyl group, a morpholinyl group, a dihydropyranyl group, a group, a group, a —PO(OR)(OR') group, wherein Rand R′independently represents a hydrogen atom or a (C-C)alkyl group, an oxetanyl group, a —Si(CH)group, a —NHCOO—(C-C)alkyl group, or a —CRRRgroup, or any of its pharmaceutically acceptable salt and pharmaceutical compositions containing them and to synthesis process for manufacturing them.

Aryl-n-aryl derivatives for treating a RNA virus infection

A compound of formula (Ic) a group, a group, a morpholinyl group, optionally substituted by a (C-C)alkyl group, a piperazinyl group, a piperidinyl group, or a —CRRRgroup, or any of its pharmaceutically acceptable salt.

A compound: wherein Xrepresents an alkenylene group, a &#x2014;NH&#x2014;CO&#x2014; group, a &#x2014;CO&#x2014;NH&#x2014; group, Yrepresents an aryl group selected from pyridyl, pyrazinyl or pyrimidinyl, Xrepresents &#x2014;O&#x2014;, &#x2014;CO&#x2014;NH&#x2014;, &#x2014;NH&#x2014;CO&#x2014;NH&#x2014;, &#x2014;OCH&#x2014;, &#x2014;NH&#x2014;CO&#x2014;, a divalent 5-membered heteroaromatic ring comprising 1 to 4 heteroatoms or &#x2014;SO&#x2014;NH&#x2014;, and Yrepresents a hydrogen atom, a hydroxyl group, a morpholinyl group, a piperidinyl group, optionally substituted by a (C-C)alkyl group, a piperazinyl group, optionally substituted by a (C-C)alkyl group, or &#x2014;CRRRor alternatively X&#x2014;Yrepresents &#x2014;CONRR, wherein Rand Rform, together with the nitrogen atom a heterocyclic ring, optionally substituted by one or two (C-C)alkyl group, by a cyclopentyl group thus forming a spirocyclopentyl, or by a trifluoromethyl group, or any of its pharmaceutically acceptable salt, for use in the treatment and/or prevention of a RNA virus infection caused by a RNA virus belonging to group IV or V of the Baltimore classification.

The present disclosure relates to the use of a compound of formula (I) or anyone of its pharmaceutically acceptable salts, in the treatment and/or prevention of an inflammatory disease; wherein: means an aromatic ring wherein V is C or N and when V is N; Q is N or O, provided that R&#x2033; does not exist when Q is O; R' independently represent a hydrogen atom or a group chosen among a (C-C)alkyl group, a halogen atom, a hydroxyl group, a &#x2014;COORgroup, a &#x2014;NOgroup, a &#x2014;NRRgroup, a morpholinyl or a morpholino group, a N-methylpiperazinyl group, a (C-C)fluoroalkyl group, a &#x2014;O&#x2014;P(&#x2550;O)&#x2014;(OR)(OR) group, a (C-C)alkoxy group and a &#x2014;CN group, and can further be a group chosen among: 

Use of quinoline derivatives for the treatment of inflammatory diseases

A use of at least one miRNA, said at least one miRNA being miR-124, as a biomarker, in particular of a viral infection, or of an efficacy of a therapeutic treatment of said viral infection.

miRNA-124 as a biomarker

A compound of formula (I): wherein A and A' independently represent a phenylene group or a pyridylene group; Ris a hydrogen atom or a (C-C)alkyl group; Ris a 2-pyridyl group, 3-pyridyl group, a 4-pyridyl group, a 2-pyrimidinyl group, a 4-pyrimidinyl group or a 5-pyrimidinyl group; Ris a carbonyl group or a sulfonyl group; and Ris a &#x2014;NH&#x2014;(CH)&#x2014;NRRgroup or a 4-methylpiperazinyl group, with a being an integer from 1 to 4, Rand Rrepresenting independently a (C-C)alkyl group, or Rand Rtogether with the nitrogen atom to which they are linked forming a heterocycle group which is chosen among a 4-methylpiperazinyl group, a morpholino group, a pyrrolidinyl group and a piperidino group; or any one of its pharmaceutically acceptable salt.

Compounds useful for treating cancer

The present disclosure is generally directed to the manufacture and use of compounds described herein for preventing, inhibiting or treating cancer, AIDS and/or premature aging, or the manufacture and use of a pharmaceutical composition comprising at least one of the compounds, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier for preventing, inhibiting or treating cancer, AIDS and/or premature aging.

Compounds and pharmaceutical compositions containing at least one of the compounds

The manufacture of 8-chloro-N-[4-(trifluoromethoxy)phenyl]quinolin-2-amine, or a pharmaceutically acceptable salt thereof, and use of 8-chloro-N-[4-(trifluoromethoxy)phenyl]quinolin-2-amine, or a pharmaceutically acceptable salt thereof, for treating various conditions, and/or inhibiting replication of HIV-1 in a patient infected with HIV-1, by administering to a patient in need thereof an effective quantity of 8-chloro-N-[4-(trifluoromethoxy)phenyl]quinolin-2-amine, or a pharmaceutically acceptable salt thereof.

Compound, and production method thereof, and methods of treatment using the compound

The present invention relates to a quinoline derivative of formula (I) or anyone of its pharmaceutically acceptable salt, or anyone of its metabolites, for use for treating or preventing a viral infection, in particular a HIV infection or a HIV-related condition in a patient; and then terminating said treatment when: the viral load is low or undetectable; and/or the level of CD4+ cell count is maintained or restored. The present invention further relates to a quinoline derivative of formula (I) as defined in claim, or anyone of its pharmaceutically acceptable salts and metabolites, for use for treating or preventing a viral infection, in particular a HIV infection or a HIV-related condition in a patient, for which an ineffectiveness or a decline in a prior anti-retroviral treatment effectiveness has been stated and to a quinoline derivative of formula (I) as defined above, or anyone of its pharmaceutically acceptable salts and metabolites, for use for treating or preventing a viral infection, in particular a HIV infection or a HIV-related condition in a patient, wherein the patient is infected by a drug-resistant viral strain, and more particularly by a drug-resistant HIV strain. 

Quinoline derivatives for use in the treatment or prevention of viral infection

The present invention relates to a compound of formula (I):  wherein A and A' independently represent a phenylene group or a pyridylene group; Ris a hydrogen atom or a (C-C)alkyl group; Ris a 2-pyridyl group, 3-pyridyl group, a 4-pyridyl group, a 2-pyrimidinyl group, a 4-pyrimidinyl group or a 5-pyrimidinyl group; Ris a carbonyl group or a sulfonyl group; and Ris a &#x2014;NH&#x2014;(CH)&#x2014;NRRgroup or a 4-methylpiperazinyl group, with a being an integer from 1 to 4, Rand Rrepresenting independently a (C-C)alkyl group, or Rand Rtogether with the nitrogen atom to which they are linked forming a heterocycle group which is chosen among a 4-methylpiperazinyl group, a morpholino group, a pyrrolidinyl group and a piperidino group; or any one of its pharmaceutically acceptable salt.

The present invention relates to a method for screening a compound useful for treating or preventing a viral infection or a virus-related condition in an individual, comprising at least the steps of: a) determining the ability of a candidate compound to promote the interaction between CBP20 and CBP80 in a sample, and b) selecting the candidate compound that is determined to promote said interaction at step a). The present invention further relates to a method for screening a compound useful for treating or preventing a viral infection or virus-related condition in an individual, comprising at least the steps of: a) determining the ability of a candidate compound to interact with CBP20 or CBP80 in a sample, and b) selecting the candidate compound that is determined to interact with CBP20 or CBP80 at step a).

Growing community of inventors

L'Hay-les-Roses, France

Romain Najman